Atrasheuskaya Alena V, Blatun Elena M, Kulak Michail V, Atrasheuskaya Alina, Karpov Igor A, Rubin Steven, Ignatyev George M
State Research Center of Virology and Biotechnology Vector, Koltsovo, Novosibirsk Region, Russia.
Vaccine. 2007 Jun 11;25(24):4651-8. doi: 10.1016/j.vaccine.2007.04.020. Epub 2007 Apr 25.
The purpose of this study was to investigate mumps vaccine failures (VF) in a highly vaccinated population of Minsk, Belarus, and to investigate a possible role for virus strain-specific immunity. During our 3-year study period, 22 adults were admitted to the Infectious Diseases Hospital in Minsk with a diagnosis of mumps. A genotype H1 mumps virus (MuV) strain was identified in all patients. Of 15 patients from whom the paired sera were collected, 9 were confirmed to have been previously vaccinated. Serological examinations indicated primary VF in seven of these cases and secondary VF in two. Despite almost all vaccinated patients possessing MuV specific IgG, few possessed neutralizing antibody to the vaccine strain and titers were nominal. Importantly, none of the sera were able to neutralize a genotype H MuV strain. Our results demonstrate the importance of assaying for neutralizing antibody and support the assertion that antigenic differences between wild type and vaccine MuV strains may play a role in cases of breakthrough infection in vaccinees.
本研究的目的是调查白俄罗斯明斯克一个高疫苗接种率人群中的腮腺炎疫苗失效(VF)情况,并研究病毒株特异性免疫可能发挥的作用。在我们为期3年的研究期间,22名成年人因腮腺炎诊断入住明斯克传染病医院。所有患者均鉴定出基因型H1腮腺炎病毒(MuV)株。在采集了配对血清的15名患者中,9名被证实之前接种过疫苗。血清学检查表明,其中7例为原发性VF,2例为继发性VF。尽管几乎所有接种过疫苗的患者都拥有MuV特异性IgG,但很少有人对疫苗株具有中和抗体,且滴度很低。重要的是,没有一份血清能够中和基因型H MuV株。我们的结果证明了检测中和抗体的重要性,并支持以下观点:野生型和疫苗MuV株之间的抗原差异可能在疫苗接种者突破性感染病例中起作用。